The study aims to prove that Nogo antibodies can make damaged nerve fibres regrow in humans (not just animals) and that this growth can lead to partial improvement of the bodys functions and sensitivity. A Phase I safety study of the anti-Nogo-A antibody trial in freshly injured paraplegic patients started in summer 2006. A placebo controlled Phase 2 “proof of concept study” is in preparation. The Nogo antibody study is being conducted in Switzerland in close cooperation between the Paraplegic Centre at Balgrist University Hospital, various trauma centres and Novartis. Read more...